-
Pipeline – Biosceptre
PIPELINE We know that our ground-breaking treatments have the potential to treat a range of malignancies and make a drastic difference to lives of millions of cancer patients, globally.
There ar...
-
About – Biosceptre
ABOUT US Biosceptre is a biopharmaceutical company focused on the development of our BRiDGECAR™ system, which combines our nfP2X7-targeted technology with highly potent chimeric antigen receptor (C...
-
Innovation – Biosceptre
INNOVATION Inspired and ambitious, our researchers are pioneers in cancer therapeutic development – focussed on developing our BRiDGECAR™ system, which combines our nfP2X7-targeted technology with ...
-
Investors – Biosceptre
INVESTORS Visionary pioneers, Biosceptre’s researchers are leading the way with the development of our multi-targeted BRiDGECAR™ system, including our nfP2X7-targeted technology, that has the poten...
-
News – Biosceptre
NEWS & MEDIA
-
Research Papers – Biosceptre
RESEARCH PAPERS
PUBLISHED PAPERS & PRESENTATIONS ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival
SM Gilbert, CJ Oliphant, S. Hassan, AL ...